Received: 2 June 2023
Accepted: 7 August 2023
First Online: 23 August 2023
: J. Elshof reports grants and speaking fees from Vivisol B.V., and grants from Fisher & Paykel, outside the submitted work. P.J. Wijkstra reports grants and consulting fees from Philips B.V., grants from Resmed Ltd., and a leadership role (treasurer) in the ERS board, outside the submitted work. M.L. Duiverman reports grants from Philips B.V., Fisher & Paykel, Vivisol B.V., Resmed Ltd. and Löwenstein B.V., speaking fees from Vivisol B.V., Resmed Ltd., Novartis, Chiesi, Breas and AstraZeneca, and a leadership role (chair group NIV) in ERS assembly 2. The other authors declare that they have no competing interests.
: The need for formal ethics approval and informed consent was waived by the medical ethics committee of the University Medical Center Groningen.
: Not applicable.